Prescription medicine
Suzetrigine Brand names: Journavx
Suzetrigine (Journavx) is a prescription medicine with an FDA approval on record since 2025. No generic is listed; pharmacies paid $15.41 per Journavx 50 mg tablet in the October 7, 2026 NADAC survey.
- No generic listed
Check it at the source: the suzetrigine FDA label on DailyMed (effective April 13, 2026, Vertex Pharmaceuticals Incorporated); the NDA 219209 record on Drugs@FDA; every suzetrigine label on DailyMed.
Highlights of the record
FDA label of April 13, 2026; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026; NADAC October 7, 2026
Used for
From the label: indications and usageJOURNAVX is indicated for the treatment of moderate to severe acute pain, including postoperative pain, in adults.
Forms and strengths
- 50 mg
Film-coated tablet.
On the market
- Earliest approval on file
- January 30, 2025 Journavx, Vertex Pharms Inc; Drugs@FDA’s file, where older or withdrawn approvals can be missing
- Generic approvals
- No generic approved
- Labelers listed (NDC)
- 2 of which 0 under generic applications, 2 under brand applications, repackagers included
- Last listed patent
- December 4, 2040 Journavx tablets; not a generic launch date
Supply and safety
- Pharmacy cost (NADAC)
- $15.41 per tablet Journavx 50 mg tablet
- Shortage (FDA)
- No current entry
- Recalls by its makers (FDA)
- No recall recorded
- FAERS reports
- 1,274 through July 30, 2026
What is suzetrigine used for?
From the label: indications and usageJOURNAVX is indicated for the treatment of moderate to severe acute pain, including postoperative pain, in adults. JOURNAVX is a sodium channel blocker indicated for the treatment of moderate to severe acute pain, including postoperative pain, in adults.
Conditions named in the indications of suzetrigine's FDA labels, with every medicine labeled for each:
FDA pharmacologic class: Sodium Channel Blocker.
Source: FDA drug label (JOURNAVX), Vertex Pharmaceuticals Incorporated, effective April 13, 2026 (SPL set f0976da4-1d20-4517-945c-b60ed2f41c12), via openFDA; the full label on DailyMed
What does the patient leaflet for suzetrigine say first?
The FDA-approved Medication Guide or Patient Information that comes with the medicine, in its own words.
From the patient leaflet: What should I avoid while taking JOURNAVX?Do not take food or drink containing grapefruit during treatment with JOURNAVX.
From the patient leaflet: How should I store JOURNAVX?Store JOURNAVX at room temperature between 68°F to 77°F (20°C to 25°C). Keep JOURNAVX and all medicines out of the reach of children.
Source: FDA drug label (JOURNAVX), Vertex Pharmaceuticals Incorporated, effective April 13, 2026 (SPL set f0976da4-1d20-4517-945c-b60ed2f41c12), via openFDA; the full label on DailyMed
Is there a generic for suzetrigine (Journavx)?
No generic suzetrigine is approved (Drugs@FDA, October 8, 2026).
The Orange Book lists 1 patent for Journavx tablets: the compound patent runs to December 4, 2040. A patent or exclusivity date is not the date a generic goes on sale: court cases and settlements move it either way.
- 2025 earliest approval on file
- 2040 last listed patent
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What do pharmacies pay for suzetrigine (Journavx)?
In CMS's NADAC survey of October 7, 2026, pharmacies paid $15.41 per Journavx 50 mg tablet, up 4% from $14.85 on October 8, 2025. The chart's scale runs from the lowest to the highest price shown, not from zero. NADAC is what retail pharmacies paid their wholesalers, per unit, in CMS's monthly survey; what a patient pays depends on insurance and the pharmacy.
- Journavx 50 mg tablet (brand)
| Strength and form | Brand or generic | Pharmacy cost | 30 tablets, or one pen or vial | 12-month change |
|---|---|---|---|---|
| Journavx 50 mg tablet | Brand | $15.41 per tablet | $462.39 | +4% |
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price
What does the suzetrigine label say about other medicines?
The suzetrigine label names 2 other medicines in its interaction, contraindication or warning sections. The labels of 3 other medicines name suzetrigine. The sentences are the labels' own; a label lists what its studies and reports found, not every interaction.
| Medicine named | Section | What the label says |
|---|---|---|
| Levonorgestrel | drug interactions | JOURNAVX-treated patients using hormonal contraceptives containing progestins other than levonorgestrel and norethindrone should use an additional nonhormonal contraceptive method or an alternative hormonal contraceptive during concomitant use and for 28 days after JOURNAVX discontinuation. |
| Norethindrone | drug interactions | JOURNAVX-treated patients using hormonal contraceptives containing progestins other than levonorgestrel and norethindrone should use an additional nonhormonal contraceptive method or an alternative hormonal contraceptive during concomitant use and for 28 days after JOURNAVX discontinuation. |
Other labels that name suzetrigine
Source: FDA drug label (JOURNAVX), Vertex Pharmaceuticals Incorporated, effective April 13, 2026 (SPL set f0976da4-1d20-4517-945c-b60ed2f41c12), via openFDA; the full label on DailyMed
What do FAERS reports show for suzetrigine?
The FDA Adverse Event Reporting System holds 1,274 reports that list suzetrigine among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 7 are coded as a death and 67 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.
Reports received each year
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
What else is labeled for the same conditions as suzetrigine?
34 other medicines are given the same way (oral) and in the same FDA class as suzetrigine or labeled mainly for the same use (pain), the same class first. Pain lists all 80 medicines labeled for it, by any route. The first 8 are below. They are listed as records, not as substitutes: whether one can replace another is a prescriber's decision.
| Medicine | Shared indication | Generic labelers (oral) | Pharmacy cost | Shortage |
|---|---|---|---|---|
| Aspirin | Pain | none listed | $0.0142 per tablet 81 mg tablet | A presentation being discontinued |
| Acetaminophen and hydrocodone | Pain | 38 labelers | $0.152 per tablet 10-325 mg tablet | No current entry |
| Diclofenac | Pain | 67 labelers | $0.0619 per tablet 75 mg tablet | A presentation being discontinued |
| Oxycodone | Pain | 34 labelers | $0.0884 per tablet 5 mg tablet | No current entry |
| Acetaminophen and oxycodone | Pain | 30 labelers | $0.183 per tablet 7.5-325 mg tablet | A presentation being discontinued |
| Tramadol | Pain | 40 labelers | $0.0248 per tablet 50 mg tablet | No current entry |
| Morphine | Pain | 17 labelers | $0.226 per tablet 15 mg tablet | In shortage |
| Phenazopyridine | Pain | none listed | $0.154 per tablet 100 mg tablet | No current entry |
Source: FDA drug labels (indications), NDC Directory, NADAC of October 7, 2026, FDA shortages (October 8, 2026)
What next?
- Suzetrigine side effects
- the label's list beside FAERS reports
- Check an interaction
- what two or more labels say about each other